Leqembi Treatment Begins in Sweden Despite Public Funding Hurdles
Event summary
- First Swedish patient treated with Leqembi outside clinical trials post-EU approval in April 2025.
- Treatment initiated at private clinic Executive Health after negative public funding recommendation.
- BioArctic and Eisai's collaboration spans 20+ years, originating from Uppsala University research.
- Leqembi approved in 53 countries, with regulatory reviews ongoing in 6 additional regions.
The big picture
Leqembi's availability in Sweden marks a strategic milestone in the global rollout of Alzheimer's disease treatments targeting amyloid pathology. The shift to private clinics following public funding rejection highlights the tension between innovative therapies and cost-containment pressures in national healthcare systems. With approvals in 53 countries and ongoing reviews, Leqembi's commercial potential hinges on navigating diverse regulatory and reimbursement landscapes.
What we're watching
- Market Expansion
- Whether BioArctic and Eisai can overcome public funding barriers in other Nordic countries.
- Regulatory Dynamics
- The pace at which additional countries approve Leqembi for broader use.
- Commercial Strategy
- How the private clinic model will scale to meet unmet demand in Sweden.